Adults with SBMA have elevated levels of NfL and GFAP, two biomarkers for nerve damage, in their cerebrospinal fluid, a study ...

The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York state approval as part of the permitting process.

In Huntington’s disease research, biomarkers are the secret weapon for spotting treatment effects. A new blood study uncovers two proteins, CAP1 and CAPZB, that, with additional work, could help track ...

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to ...

A new study, published in Nature Medicine, has investigated the potential of specific biomarkers such as tau217, ...

Scientists discovered a genetic marker that predicts before MS therapy whether glatiramer acetate or interferon is likely to ...

Reports Q2 revenue $27k vs $91k last year. “We look forward to engaging with the FDA in our upcoming meeting this quarter focused on the extensive ...

A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in patients with the degenerative ...

The Company plans to hold an end-of-Phase 2 Type B meeting with the FDA in the third quarter of 2025. This meeting will review results from the Phase 2 VISIONARY-MS trial and discuss the planned Phase ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Enrollment is complete for a Phase 2 trial testing Zenas Biopharma's obexelimab in relapsing MS, with results expected later ...

A non-verbal dichotic listening test may help reveal how dementia leads to hearing loss, according to a presentation at the ...